• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does New US Orphan Drug Status For Zoci Reshape The Bull Case For Zai Lab (ZLAB)?

    Simply Wall St·08/05/2026 20:27:35
    Listen to the news
    • Zai Lab recently reported that the U.S. FDA granted Orphan Drug Designation to its DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan (Zoci), for treating neuroendocrine carcinomas, a group of aggressive cancers with limited options.
    • This second orphan designation, following a similar decision in Europe, underlines Zoci’s potential as a first-in-class therapy in a difficult tumor type.
    • We’ll now examine how this new Orphan Drug Designation for Zoci could influence Zai Lab’s investment narrative and long-term pipeline potential.

    Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

    Zai Lab Investment Narrative Recap

    To own Zai Lab, you need to believe its mix of partnered assets and emerging proprietary programs can eventually turn growing revenue into sustainable profitability, despite ongoing losses and competition in China. The new U.S. Orphan Drug Designation for Zoci supports the long term pipeline story in difficult cancers, but it does not materially change the near term catalyst around upcoming earnings or the key risk of high costs against still negative net income.

    Among recent announcements, the April 2026 AACR data for Zoci and the start of a global Phase 3 trial are most relevant. Together with the new U.S. and earlier European orphan designations, they frame Zoci as a central pipeline asset that could, if development progresses successfully, become an important driver in Zai Lab’s oncology portfolio and a focal point for future data readouts and regulatory milestones.

    Yet alongside this opportunity, you should be aware that...

    Read the full narrative on Zai Lab (it's free!)

    Zai Lab's narrative projects $832.0 million revenue and $157.9 million earnings by 2029. This requires 22.4% yearly revenue growth and a $336.0 million earnings increase from -$178.1 million today.

    Uncover how Zai Lab's forecasts yield a $33.30 fair value, a 80% upside to its current price.

    Exploring Other Perspectives

    ZLAB 1-Year Stock Price Chart
    ZLAB 1-Year Stock Price Chart

    Some of the lowest forecast analysts painted a far more cautious picture, assuming revenue of about US$712,100,000 and earnings near US$105,000,000 by 2029, so you should weigh this more pessimistic view against the new Zoci designations and your own expectations before deciding how much optimism is reasonable.

    Explore 4 other fair value estimates on Zai Lab - why the stock might be worth over 4x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.